Buscar en
Enfermedades Infecciosas y Microbiología Clínica (English Edition)
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica (English Edition) The association between Fusobacterium nucleatum and cancer colorectal: A systema...
Journal Information
Vol. 40. Issue 5.
Pages 224-234 (May 2022)
Visits
887
Vol. 40. Issue 5.
Pages 224-234 (May 2022)
Original article
Full text access
The association between Fusobacterium nucleatum and cancer colorectal: A systematic review and meta-analysis
La asociación entre Fusobacterium nucleatum y el cáncer colorrectal: una revisión sistemática y metaanálisis
Visits
887
Paola Villar-Ortegaa, Manuela Expósito-Ruizb, Miguel Gutiérrez-Sotoc, Miguel Ruiz-Cabello Jiménezd, José María Navarro-Maríe, José Gutiérrez-Fernándeza,e,
Corresponding author
josegf@go.ugr.es

Corresponding author.
a Departamento de Microbiología, Universidad de Granada-Instituto de Investigación BioSanitaria-ibs-Granada, Granada, Spain
b Departamento de Bioestadística de FIBAO, Hospital Universitario Virgen de las Nieves-Instituto de Investigación BioSanitaria-ibs-Granada, Granada, Spain
c Departamento de Urgencias, Hospital de Montilla, Montilla, Córdoba, Spain
d UGC de Digestivo, Hospital Universitario Virgen de las Nieves-Instituto de Investigación BioSanitaria-ibs-Granada, Granada, Spain
e Laboratorio de Microbiología, Hospital Universitario Virgen de las Nieves-Instituto de Investigación BioSanitaria-ibs-Granada, Granada, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (5)
Show moreShow less
Tables (3)
Table 1. Systematic review of the literature published in the MEDLINE database and accessed via the PubMed interface until 1 January 2020 on the relationship between Fusobacterium nucleatum and colorectal cancer.
Table 2. List of the 18 studies that compared, in Cases and Controls-1, positivity for Fusobacterium nucleatum infection markers in intestinal biopsy samples using molecular biology.
Table 3. List of nine studies that compared, in Cases and Controls-2, positivity for Fusobacterium nucleatum infection markers in intestinal biopsy samples using molecular biology.
Show moreShow less
Abstract
Introduction

The etiological factors of colorectal cancer (CRC) are not precisely known, although genetic and environmental factors have been implicated. A possible association with Fusobacterium nucleatum may provide opportunities for an early diagnosis.

Objective

To review studies that address the association between F. nucleatum and CRC.

Methods

The MEDLINE PubMed database was searched using the terms «colorectal cancer» and “Fusobacterium nucleatum”, retrieving publications published up to January 1 2020. Stata software was used for a meta-analysis.

Results

The systematic review included 57 articles. Meta-analysis results indicated a more frequent presence of F. nucleatum in CRC tumour tissue samples in comparison to control samples of healthy tissue, with an odds ratio of 4.558 (95% CI: 3.312−6.272), and in comparison, to control samples of colorectal adenomas, with an odds ratio of 3.244 (95 % CI: 2.359−4.462).

Conclusion

There is a more frequent resence of F. nucleatum in the CRC. However, further studies are needed to verify this relationship.

Keywords:
Colorectal cancer
Fusobacterium nucleatum
Microbiota
Dysbiosis
Chronic inflammation
Resumen
Introducción

Se desconocen los factores etiológicos exactos del cáncer colorrectal (CCR), aunque se ha intentado relacionar con factores genéticos y ambientales. La posible asociación con Fusobacterium nucleatum podría abrir posibilidades en el diagnóstico precoz.

Objetivo

Revisar los estudios que analizan la asociación entre F. nucleatum y el CCR.

Métodos

Se utilizaron las publicaciones disponibles en la base de datos MEDLINE PubMed hasta el día 1 de enero de 2020, que incluían los términos «cáncer colorrectal» y «Fusobacterium nucleatum». Se realizó un metaanálisis con el software Stata.

Resultados

Un total de 57 artículos fueron incluidos en la revisión sistemática. El metaanálisis indicó una mayor presencia de F. nucleatum en muestras de tejido tumoral de CCR, con respecto a muestras control de tejido sano, con una odds ratio de 4,558 (IC 95%: 3,312–6,272), y cuando se utilizaron muestras control de adenomas colorrectales, con una odds ratio de 3,244 (IC 95%: 2,359–4,462).

Conclusión

Hay una mayor presencia de F. nucleatum en el CCR. Sin embargo, se necesitan estudios que demuestren esta relación.

Palabras clave:
Cáncer colorrectal
Fusobacterium nucleatum
Microbiota
Disbiosis
Inflamación crónica
Full Text
Introduction

The aetiology of colorectal cancer (CRC) is multifactorial and includes genetic and epigenetic abnormalities1. Extrinsic factors such as intestinal dysbiosis might also play a role2; however, interindividual variability exists due to multiple genetic and environmental factors3. Hence, it is of special interest to investigate the possibility of a common microbial denominator.Fusobacterium nucleatum (FN) is among the most extensively studied bacteria4–6. It is a Gram-negative anaerobic bacterium that resides in the oral cavity as commensal microbiota, but it is also an opportunistic pathogen in periodontal diseases, primarily in gingivitis and periodontitis7. Its pathogenic power lies in its virulence factors, including: the presence of fimbriae, lipopolysaccharides, factors inhibiting chemotaxis of polymorphonuclear leukocytes and the production of toxic tissue metabolites8. However, its most significant virulence factor is FadA adhesin. This has been shown to be the greatest stimulant of inflammation as it creates a chronic proinflammatory environment that activates oncogenic signalling, thus stimulating epithelial cells9,10. Recent studies have demonstrated an increase in FadA in neoplastic CRC tissue, along with other proinflammatory markers such as COX-2, IL-8, IL-6, IL1ß and TNF-α11.

The possibility that FN is involved in the process of carcinogenesis could open up new avenues for early diagnosis. This justifies a comprehensive analysis of the current evidence on the relationship between FN and CRC. The objective of this study was to integrate the information available on the relationship between FN and CRC in a meta-analysis.

Material and methods

The meta-analysis had a qualitative component (systematic review) and a quantitative component. The systematic review consisted of a description of the published studies, considering individual studies to be study “subjects”. A systematic search was conducted of all articles published in English or Spanish in journals indexed in MEDLINE, ISI Web of Knowledge and the Cochrane Library. The search terms used were “colorectal cancer” and “Fusobacterium nucleatum”. The selection criteria were the time limit (the search was restricted to all articles published in hard-copy and/or electronic format prior to January 2020), study type (research studies were selected) and language (the search was confined to articles written in English or Spanish). The following were excluded: studies on the relationship between FN and diseases other than CRC, studies on the relationship between CRC and bacteria other than FN, studies on the isolation of FN in species other than human beings, and reviews. The studies had to include patients with CRC, and they had to have the objective of directly or indirectly looking for FN and attempting to establish a possible association between FN infection and CRC. An internal quality system was used; this verified the reliability of the chosen method above, based on thorough review of each publication with tracing of the references in the publications to avoid missed studies.

The qualitative component referred to the statistical grouping of the results, with individual studies acting as research subjects, yielding, within and across publications, the 95% confidence interval, the odds ratio (OR) and the weights of the studies. The weighted mean was estimated by means of the random-effects model using DerSimonian and Laird’s method12, which is affected to a lesser extent by heterogeneity between studies. The inverse-variance test was used to assess heterogeneity. In addition, Higgins’s I2 inconsistency index was calculated; the value of this index indicates the percentage of variability due to heterogeneity between studies. Values over 75% indicate a strong heterogeneity level and would suggest a need to conduct further studies. Begg’s13 and Egger’s14 tests were used to detect publication bias. Data analysis was performed with the Stata 14 software programme.

ResultsSystematic review

The article search collected 199 publications; of them, 57 studies whose online version at least was published between 2011 and 2019 were selected (Table 1 and Fig. 1). Non-tumour area control samples were called Controls-1 (40 studies — 70.2%: 15 samples of adjacent non-tumour tissue, four faecal samples, two blood samples, one saliva sample, 18 non-tumour tissue samples). Adenoma samples were called Controls-2 (16%–28.1%). The Test-1 column indicates the test described by the authors to detect the micro-organism. In addition, some of the studies included the use of additional laboratory tests, called Test-2. Finally, the most salient conclusion of the research articles was also collected (“Article comments” column).

Table 1.

Systematic review of the literature published in the MEDLINE database and accessed via the PubMed interface until 1 January 2020 on the relationship between Fusobacterium nucleatum and colorectal cancer.

Author  Year Physical publication  Total sex (f:m)  Cases CRC  Sex Cases CRC (f:m)  Control-1: No CRC (n)  Sex Control-1  Description Group Control-1  Control-2: Adenomas (n)  Sex Control-2  What was analysed?  Test 1  Test 2  FN+/total Cases  FN+/total Control-1  FN+/total Control-2  Article comments 
Castellarin et al.15  2012  NI  11  NI  99  NI  Adjacent non-tumour tissue  NI  NI  RNA  PCR  NI  11/11  9/11  NI  Higher rate of FN in CRC than in normal tissue 
Rubinstein et al.16  2013  NI  51  NI  14  NI  Tissue from tumour-free subjects  NI  NI  mRNA  PCR  NI  NI  NI  NI  Higher rate of FadA in CRC than in normal tissue 
Kostic et al.4  2013  NI  27  NI  31  NI  Tissue from tumour-free subjects  28  NI  DNA and RNA  PCR  FISH  27/27  15/31  24/28  FN creates a proinflammatory state that promotes progression to CRC 
Warren et al.17  2013  NI  65  NI  65  NI  Adjacent non-tumour tissue  NI  NI  rRNA  Metatranscriptomics  NI  NI  NI  NI  Higher rate of FN in CRC than in adjacent healthy tissue 
Flanagan et al.18  2014  NI  122  NI  174  NI  Adjacent non-tumour tissue  52  NI  DNA  PCR  NI  70/122  33/174  12/52  FN can be used as a marker for CRC 
Mira-Pascual et al.19  2014  NI  NI  NI  Tissue from tumour-free subjects  NI  NI  DNA and RNA  PCR  Pyrosequencing  2/7  0/5  NI  The increase in the levels of the bacteria studies was correlated with CRC 
Tahara et al.20  2014  NI  149  NI  89  NI  Adjacent non-tumour tissue  NI  NI  DNA  PCR  NI  78/149  27/89  NI  Higher rate of FN in CRC than in controls 
Ito et al.21  2015  NI  511  225:286  20  NI  Tissue from tumour-free subjects  456  39:59  DNA  PCR  NI  286/511  3/20  142/456  Higher rate of FN in CRC than in controls 
Mima et al.22  2015  NI  598  NI  558  NI  Adjacent non-tumour tissue  NI  NI  DNA  PCR  NI  76/598  19/558  NI  FN creates a proinflammatory state that promotes progression to CRC 
Yu et al.10  2015  NI  42  NI  52  NI  Adjacent non-tumour tissue  47  NI  DNA  PCR  NI  NI  NI  NI  Higher rate of FN in CRC than in controls 
Fukugaiti et al.23  2015  4:13  2:5  10  2:8  Faeces  NI  NI  DNA  PCR  FISH  7/7  9/10  NI  Higher rate of FN in CRC than in controls 
Nosho et al.24  2016  NI  511  225:286  NI  NI  No control tissue  NI  NI  DNA  PCR  NI  44/511  NI  NI  Lower rate of positive results for FN in the Japanese cohort 
Repass et al.25  2016  NI  40  NI  40  NI  Adjacent non-tumour tissue  NI  NI  DNA  PCR  NI  NI  NI  NI  Higher rate of FN in CRC than in normal tissue 
Li et al.26  2016  46:55  101  46:55  101  46:55  Adjacent non-tumour tissue  NI  NI  DNA  PCR  FISH  88/101  NI  NI  Larger amount of FN in CRC is associated with lower survival time 
Yu et al.27  2016  NI  93  NI  20  NI  Tissue from tumour-free subjects  112  NI  DNA  PCR  NI  62/93  4/20  47/112  FN might play a role in the serrated pathway of carcinogenesis for CRC 
Mima et al.28  2016  NI  1,102  NI  NI  NI  No control tissue  NI  NI  DNA  PCR  NI  138/1,102  NI  NI  Increases the rate of FN from CRC of the rectum to caecal carcinoma 
Yu et al.5  2017  NI  74  NI  54  NI  Tissue from tumour-free subjects  NI  NI  DNA  PCR  NI  39/74  2/54  NI  FN promotes CRC progression through modulation of autophagy pathways 
Suehiro et al.29  2017  NI  158  NI  60  NI  Tissue from tumour-free subjects  19  NI  DNA  PCR  NI  NI  NI  NI  Mean copies of FN: 17.5 in the control group, 122 in the adenoma group, 317 in the CRC group 
Liang et al.30  2017  NI  203  NI  236  NI  Tissue from tumour-free subjects  NI  NI  DNA  PCR  Metagenomic sequencing  NI  NI  NI  Higher rate of FN in CRC than in controls 
Wong et al.31  2017  NI  104  NI  102  NI  Tissue from tumour-free subjects  103  NI  DNA  PCR  NI  NI  NI  NI  Larger amount of FN in adenomas compared to controls p = 0.022 
Mehta et al.32  2017  NI  1,019  NI  NI  NI  No control tissue  NI  NI  DNA  PCR  NI  125/1,019  NI  NI  The association between diet and CRC is modified by FN 
Chen et al.33  2017  NI  98  40:58  NI  NI  No control tissue  NI  NI  DNA  FISH  NI  61/98  NI  NI  Invasive FN activates the beta-catenin signalling pathway 
Ye et al.34  2017  NI  25  NI  25  NI  Adjacent non-tumour tissue  NI  NI  DNA  PCR  NI  4/25  2/25  NI  Higher rate of FN in CRC than in controls 
Amitay et al.35  2017  220:280  46  15:31  231  121:110  Tissue from tumour-free subjects  223  84:139  DNA  PCR  NI  25/46  58/231  53/223  Higher rate of FN in CRC than in controls 
Park et al.36  2017  82:78  160  82:78  NI  NI  No control tissue  NI  NI  DNA  PCR  NI  107/160  NI  NI  The larger amount of FN in tumour samples is correlated with the presence of intratumoural macrophages 
Eklöf et al.37  2017  NI  39  19:20  65  30:35  Tissue from tumour-free subjects  NI  NI  DNA  PCR  NI  27/39  15/65  NI  Larger amount of FN in CRC than in controls 
Bullman et al.38  2017  NI  77  NI  NI  NI  No control tissue  NI  NI  RNA  PCR  FISH  45/77  NI  NI  The reduction in FN with antibiotics causes less cancer proliferation 
Drewes et al.39  2017  NI  58  NI  34  NI  Tissue from tumour-free subjects  NI  NI  RNA  PCR  FISH  17/58  1/34  NI  Larger amount of bacteria in CRC than in healthy tissue 
Yamaoka et al.40  2018  NI  100  NI  72  NI  Adjacent non-tumour tissue  NI  NI  DNA  PCR    75/100  46/72  NI  Larger amount of FN in CRC than in controls 
Guevara et al.6  2018  NI  37  NI  37  NI  Tissue from tumour-free subjects  NI  NI  Anti-FN antibodies  ELISA  NI  37/37  12/37  NI  The FN Fap2 protein is antigenic 
Dai et al.41  2018  206:320  255  92:163  271  114:157  Faeces  NI  NI  DNA  Metagenomics  NI  NI  NI  NI  Higher rate of FN in CRC than in controls 
Liu et al.42  2018  NI  2,759  NI  NI  NI  No control tissue  NI  NI  DNA  PCR  NI  951/2,759  NI  NI  Positive association between the empirical dietary inflammatory pattern (EDIP) and FN + CRC 
Chen et al.43  2018  NI  25  NI  NI  No control tissue  NI  DNA  FISH  Immunofluorescence  NI  NI  NI  Greater expression of TOX and CD4+ in FN − tissue versus FN + tissue. Negative correlation between FN abundance and TOX expression 
Guo et al.44  2018  NI  215  NI  156  NI  Tissue from tumour-free subjects  NI  NI  DNA  PCR  NI  NI  NI  NI  The FN/Bifidobacterium ratio had a sensitivity of 84.6% and a specificity of 92.3% in detecting CRC 
Komiya et al.45  2018  NI  14  NI  NI  NI  No control tissue  NI  NI  DNA  PCR  NI  8/14  NI  NI  FN samples in tumour tissue and saliva 
Lee et al.46  2018  NI  246  NI  NI  NI  No control tissue  NI  NI  DNA  PCR  NI  NI  NI  NI  High levels of FN are associated with lower survival in CRC metastases 
Rezasoltani et al.47  2018  NI  NI  NI  31  15:16  Tissue from tumour-free subjects  87  33:54  DNA  PCR  NI  NI  NI  NI  Significant relationship between polyp size and FN measurement 
Hamada et al.48  2018  609:432  1,041  609:432  NI  NI  No control tissue  NI  NI  DNA  PCR  NI  135/1,041  NI  NI  The association between FN and CRC varies depending on whether the CRC has an abnormal microsatellite pathway 
Oh et al.49  2018  231:362  593  231:362  NI  NI  No control tissue  NI  NI  DNA  PCR  NI  204/593  NI  NI  The tumour prognosis in relation to FN depends on the CRC location 
Proença et al.50  2018  NI  43  NI  70  NI  Adjacent non-tumour tissue  27  NI  DNA  PCR  NI  33/43  23/70  14/27  FN is a risk factor for CRC 
Zhang et al.51  2019  41:53  94  41:53  NI  NI  No control tissue  NI  NI  DNA  PCR  Microarray  21/90  NI  NI  FN induces expression of the BIRC3 gene in CRC 
Saito et al.52  2019  30:51  24  7:17  10  7:3  Tissue from tumour-free subjects  47  16:31  rRNA  PCR  NI  14/24  NI  28/47  FN may be associated with CRC and adenomas, and is a potential diagnostic marker for both 
Guo et al.53  2019  NI  46  NI  36  NI  Blood  NI  NI  DNA  Genomic sequencing  NI  NI  NI  NI  Greater presence of FN in tumour tissue than in blood samples 
Feng et al.54  2019  13:12  15  8:7  10  5:5  Tissue from tumour-free subjects  NI  NI  DNA  PCR  Western blot  10/15  5/10  NI  CREB protein expression is correlated with CRC metastasis whether in FN + or in FN− 
Tunsjø et al.55  2019  NI  25  NI  22  NI  Tissue from tumour-free subjects  25  NI  DNA  PCR  16S rRNA sequencing  15/25  5/25  4/22  PCR for FN detection could be included as a CRC biomarker 
Bundgaard-Nielsen et al.56  2019  141:132  99  55:44  76  35:41  Adjacent non-tumour tissue  96  51:47  DNA  PCR  16S rRNA sequencing  23/99  NI  3/96  There is no evidence that FN plays a role in the onset of adenomas, but it might play a role in the transition from adenoma to CRC 
Guven et al.57  2019  NI  71  NI  77  NI  Saliva from cancer-free controls  NI  NI  DNA  PCR  NI  NI  NI  NI  Larger amount of FN in saliva from patients with CRC compared to controls 
Yachida et al.58  2019  NI  258  NI  291  NI  Faeces  67  NI  DNA  Capillary electrophoresis  Metagenomic and metabolomic study  NI  NI  NI  FN abundance is correlated with tumour progression from intramucosal carcinoma to more advanced stages 
Leung et al.59  2019  10:9  19  10:9  19  10:9  Adjacent non-tumour tissue  NI  NI  DNA  PCR  NI  NI  NI  NI  Higher rate of FN in CRC than in normal tissue 
Kunzmann et al.60  2019  60:130  190  60:130  190  60:130  Adjacent non-tumour tissue  NI  NI  DNA  PCR  NI  61/190  129/190  NI  FN is more abundant in tumour tissue than surrounding tissue 
Butt et al.61  2019  NI  485  NI  485  NI  Blood  NI  NI  Anti-FN antibodies  Serology  NI  NI  NI  NI  Anti-FN antibodies have no association with the risk of developing CRC 
De Carvalho et al.62  2019  NI  152  NI  57  NI  Adjacent non-tumour tissue  NI  NI  DNA  PCR  NI  35/152  6/57  NI  Detection of FN DNA is associated with proximal tumour location; positivity for MSI or BRAF mutation; loss of MLH1, MSH2 or PMS2; and lower survival 
Chen et al.63  2019  36:55  91  36:55  NI  NI  No control tissue  NI  NI  DNA  PCR  NI  25/91  NI  NI  Larger amount of FN in CRC tissue is associated with lower survival time 
Mima et al.64  2019  208:304  256  208:304  NI  NI  No control tissue  NI  NI  DNA  PCR  NI  140/256  NI  NI  Larger amounts of FN and other bacteria associated with CRC increase the risk of anastomotic rupture following surgery 
Liang et al.65  2019  NI  274  NI  353  NI  Faeces  353  NI  DNA  PCR  Faecal immunohistochemistry test  71/274  97/385  145/353  Identification of m3 marker for CRC diagnosis 
Haruki et al.66  2019  423:301  724  423:301  NI  NI  No control tissue  NI  NI  DNA  PCR  NI  99/724  NI  NI  Inverse association between FN amount and tumour expression of BECN1 
Chen et al.67  2019  NI  148  NI  NI  NI  No control tissue  NI  NI  DNA and RNA  PCR  FISH  88/148  NI  NI  FN is found in larger amounts in CRC with metastases 

CRC: colorectal cancer; FN: Fusobacterium nucleatum; NI: no information.

Fig. 1.

Systematic review flow chart.

(0.18MB).

An increase in the number of studies published over the years was confirmed, but only in 2017 did this research significantly increase. The sex of the cases was reported in 20 (35.1%) studies overall, 11 (19.3%) Controls-1 studies and five (31.2%) Controls-2 studies. Until 2015, no studies reported the sex of the study participants. The most recent studies have tended to specify the sex of the study population. Analysis of the distribution of the studies with quantitative data found that such data were indicated in 40 (70.2%) Cases articles, 22 (38.6%) Controls-1 articles and 10 (25%) Controls-2 articles.

Quantitative analysis

Regarding the number of positive results in the CRC samples, the highest rates of positive results were found in the studies by Castellarin et al.15, Kostic et al.4, Fukugaiti et al.23 and Guevara et al.6, in which all CRC samples analysed yielded a positive result in laboratory tests. By contrast, the lowest rate of positive results was found in a study by Nosho et al.24, in which just 8.6% of samples had a positive result. The number of samples for the Cases in each study varied widely. The lowest number was found in studies by Mira-Pascual et al.19 and Fukugaiti et al.23, with a total of seven cases analysed in each study. The largest sample size for the Cases corresponded to a study by Liu et al.42, with an analysis of 2759 samples. It should be noted that just four (7%) studies had more than 1000 individuals with CRC, and that they were conducted between 2017 and 2018.

Table 2 shows the studies (18 out of 40, 45%) that compared, in Cases and Controls-1, positivity for FN infection markers with quantitative data from samples of colon tissue using molecular biology tests. The studies by Mima et al.28, Flanagan et al.18 and Tahara et al.20 were notable for their weight. All of them had a weight in excess of 10%. The overall OR estimate for the individual results obtained in these studies yielded a result of 4.558 (95% CI: 3.312−6.272), leading to the conclusion that there was a significant association (p < 0.001) between FN and CRC when Controls-1 were used. To calculate heterogeneity, the inverse-variance test was performed, with a value of χ2 exp. = 30.54, with 17 degrees of freedom and p = 0.023, meaning that the differences found between the studies were not due to chance. The heterogeneity study was corroborated using Higgins’s I2, with a result of I2=44,3% (Table 2 and Fig. 2). There was no obvious publication bias, as indicated in Begg’s and Egger’s tests, which were not significant (p = 0.767 and p = 0.210, respectively) (Fig. 3).

Table 2.

List of the 18 studies that compared, in Cases and Controls-1, positivity for Fusobacterium nucleatum infection markers in intestinal biopsy samples using molecular biology.

Study  OR  95% CI  % weight 
Castellarin et al., 2011  6.053  0.258−142.040  0.96 
Kostic et al., 2013  58.548  3.282−1,044.602  1.14 
Flanagan et al., 2014  5.752  3.413−9.693  10.85 
Mira-Pascual et al., 2014  5.000  0.192−130.024  0.90 
Tahara et al., 2014  2.523  1.449−4.393  10.46 
Ito et al., 2015  7.203  2.085−24.884  4.62 
Mima et al., 2015  4.130  2.463−6.926  10.91 
Yu et al., 2017  28.971  6.567−127.806  3.55 
Yu et al., 2016  8.000  2.465−25.968  4.96 
Ye et al., 2017  2.190  0.363−13.219  2.61 
Amitay et al., 2017  3.551  1.850−6.815  9.34 
Yamaoka et al., 2018  1.696  0.876−3.282  9.24 
Eklöf et al., 2017  7.500  3.074−18.297  6.97 
Drewes et al., 2017  13.683  1.730−108.242  2.06 
Proença et al., 2018  6.743  2.838−16.026  7.20 
Feng et al., 2019  2.000  0.388−10.309  3.04 
Tunsjø et al., 2019  6.000  1.693−21.262  4.50 
De Carvalho et al., 2019  2.543  1.007−6.421  6.68 
D + L pooled OR  4.558  3.312−6.272  100.00 

Heterogeneity χ2 = 30.54 (gl = 17) p = 0.023.

I2 (variation in OR that can be attributed to heterogeneity) = 44.3 %.

Estimated variance between studies tau-squared = 0.1736.

Test of OR = 1: z = 9.31, p = 0.000.

Fig. 2.

Forest plot of the 18 studies that compared, in Cases and Controls-1, positivity for Fusobacterium nucleatum infection markers in intestinal biopsy samples using molecular biology.

(0.27MB).
Fig. 3.

Funnel plot of the 18 studies that compared, in Cases and Controls-1, positivity for Fusobacterium nucleatum infection markers in intestinal biopsy samples using molecular biology.

(0.06MB).

Table 3 shows the studies (nine out of 16, 56.25%) that compared, in Cases and Controls-2 (colorectal adenomas), positivity for genetic markers of FN infection with quantitative data from samples of colon tissue using molecular biology tests. The studies by Ito et al.21, Flanagan et al.18, Yu et al.27 and Amitay et al.35 all had notable weights, exceeding 12%. The overall OR estimate for the individual results obtained in these studies yielded a result of 3.244 (95% CI: 2.359−4.462), showing a statistically significant association between the presence of FN and CRC (p < 0.001). To analyse heterogeneity, the inverse-variance test was performed, with a value of χ2 exp. = 12.33, with eight degrees of freedom and p = 0.137, showing that there was homogeneity between the studies compared. In addition, Higgins’s I2 showed a value of 35.1%, indicating a low level of heterogeneity (Table 3 and Fig. 4).

Table 3.

List of nine studies that compared, in Cases and Controls-2, positivity for Fusobacterium nucleatum infection markers in intestinal biopsy samples using molecular biology.

Study  OR  95% CI  % weight 
Kostic et al., 2013  10.102  0.517−197.311  1.11 
Flanagan et al., 2014  4.487  2.145−9.388  12.37 
Ito et al., 2015  2.811  2.158−3.661  29.36 
Yu et al., 2016  2.766  1.562−4.899  16.85 
Amitay et al., 2017  3.819  1.980−7.366  14.35 
Proença et al., 2018  3.064  1.089−8.623  7.54 
Saito et al., 2019  0.950  0.350−2.580  7.97 
Tunsjø et al., 2019  6.750  1.755−25.956  4.86 
Bundgaard-Nielsen et al., 2019  9.382  2.713−32.442  5.59 
D + L pooled OR  3.244  2.359−4.462  100.00 

Heterogeneity χ2 = 12.33 (gl = 8) p = 0.137.

I2 (variation in OR that can be attributed to heterogeneity) = 35.1%.

Estimated variance between studies tau-squared = 0.0719.

Test of OR = 1: z = 7.24 p = 0.000.

Fig. 4.

Forest plot of the eight studies that compared, in Cases and Controls-2, positivity for Fusobacterium nucleatum infection markers in intestinal biopsy samples using molecular biology.

(0.13MB).

There was no obvious publication bias, as indicated by Begg's and Egger's tests, which were not significant (p = 0.108 and p = 0.441, respectively) (Fig. 5).

Fig. 5.

Funnel plot of the eight studies that compared, in Cases and Controls-2, positivity for Fusobacterium nucleatum infection markers in intestinal biopsy samples using molecular biology.

(0.06MB).
Discussion

This study found that the relationship between FN and CRC is a topic of growing interest, given the exponential rise in studies that have explored this relationship. With regard to the sample size of the studies, 31 (54.4%) had fewer than 100 case samples, and just four (7%) had more than 1000 samples. Similarly, in the studies published, just 22 (55%) had numerical data for Controls-1 and 10 (17.5%) had numerical data for Controls-2. Efforts have been made in recent years to correct this, however, and the most current studies have exhibited a trend towards publishing the corresponding values. Above all, future studies must report quantitative data for FN positivity in samples, as this constitutes solid evidence subject to statistical processing on the association thereof with CRC. Also important is the influence of sex on the results, which has scarcely been studied in this regard, given that such data have been omitted from many studies. The breakdown of this relationship by sex could shed light on whether sex could be considered a risk factor in relation to the presence of FN, since non-transmissible chronic diseases are related to lifestyle factors in men and women. In this systematic review, the sex of the patients was only indicated in 20 (35.1%) studies out of the total of 57 articles collected.

Similarly, future studies could examine other variables, such as diet. Some studies, including the study by Hussan et al.68, have collected data for this variable and found a fibre-rich diet to be linked to a lower risk of developing CRC despite having a larger number of FN-positive samples in the colon mucosa, which would seem contradictory.

It should also be noted that the majority of the samples analysed in the study were tissue samples. That is to say, the CRC samples were tumour tissue samples and the control samples were samples of healthy tissue, since, in theory, the study thereof should offer more complete information. From what has been published to date, it has been deduced that FN has a significant presence in CRC tissue compared to adjacent healthy tissue15,18,20,28,69, with a gradual increase in FN from healthy mucosa to adenoma and from adenoma to adenocarcinoma. This suggests that FN may play an important role as of the earliest stages of colon cancer onset4,10,18,70, that there is an association between the presence of FN and lymph node invasion by CRC15,26,71 and that FN accompanies tumour cells in metastases38. Thus it has been explained that the amount of FN in CRC is linked to stage, chemotherapy resistance, higher recurrence and lower survival, with said amount acting as an independent predictive factor10,26,28,38,70,72,73.

Just four (7%) studies tested faecal samples, one (1.8%) tested blood samples and one (1.8%) tested saliva samples, concluding that there is an overabundance of FN in the faeces of patients with CRC. FN is 132 times more abundant in the faeces of patients with CRC, and its determination has been identified as a useful marker for detecting CRC29–31, showing a sensitivity of 80.2% and a specificity of 80.7%, with these figures increasing to 92 %–93% when it is combined with faecal occult blood detection74. It would be interesting to confirm the association between FN and CRC simultaneously in samples of tissue, faeces, saliva and blood. Should research be intensified and a significant association discovered, it would have a great deal of diagnostic utility for patients, since these samples are relatively easy to collect with no need for a colonoscopy to acquire them.

Based on all studies conducted to date, the involvement of FN in the mechanism of carcinogenesis in CRC could be agreed upon, since there is a statistically significant association between the presence of FN and CRC. However, in order to determine that this bacterium is the true origin of CRC, the causality criteria, primarily temporality, direction and association, must be met75. In this case, the temporality criterion, by which the effect must be preceded by the cause, could not be demonstrated. Most studies that have investigated the association between FN and CRC have been retrospective, meaning it could not be known whether the bacterium was present before the tumour developed or was acquired later; more evidence, then, is needed to confirm this causality.

Multiple studies, including those by Mima et al.28, Flanagan et al.18 and Tahara et al.20, which are notable for their weight in the meta-analysis, confirmed that there is a relationship between FN and CRC in comparison of healthy tissue from Controls-1 and CRC Cases. However, this association must be clarified for reasons including the fact that, at present, no prospective studies have found the presence of the bacterium to precede the onset of cancer. It is now known that the aetiopathogenic substrate corresponds to the activation of a chronic inflammatory state resulting from adhesion of the bacterium through a mechanism of intestinal dysbiosis. This entire process leads to an initiation of pathways associated with colorectal carcinogenesis, notably the Wnt/beta-catenin pathway, whose dysregulation causes failures in cell growth and tumour progression76. In-depth examination of the activation of these proinflammatory pathways and the mechanisms by which they occur will open up multiple possibilities for diagnosis and treatment in one of the highest incidence cancers today, with substantial benefits in the course of this disease. Our meta-analysis found FN to be more abundant in colorectal cancer tissue samples compared to healthy tissue with an OR of 4.558 and a 95% confidence interval of 3.312−6.272, confirming the significant association between the presence of FN in the tissue samples with the development of CRC. However, the meaning of this relationship must be clarified with prospective studies that confirm the temporality of the association. Other meta-analysis such as Hussan et al.’s68 have also pointed to this need.

In addition, recent studies such as Yu et al.’s70 have described the role of FN in chemoresistance in patients with CRC, indicating that an increased amount of FN in tumour tissue is linked to a higher rate of chemoresistance. For this reason, it would be useful to conduct further studies on survival time in patients in relation to FN levels in tumour tissue, since this could signify the existence of more therapeutic targets in this disease such as bacteria-eradicating treatment.

In the case of the comparison between the Controls-2 (colorectal adenomas) and the CRC Cases, it is important to note that not the all articles used samples of the same types of colorectal adenomas; a wide variety of histological types falling under the label of “colorectal adenoma” were studied. Furthermore, at present, fewer studies have linked the presence of FN to colorectal adenomas. The scarcity of articles, coupled with the lack of uniform criteria for sample selection, indicates that this association, as well as the question of whether FN contributes less to an adenoma forming and more to it becoming malignant, should be studied in greater depth in the future.

Multiple articles, including but not limited to Mima et al.28, Yu et al.5 and Lee et al.46, have found a relationship between CRC survival and the presence or absence of FN, though no studies have found FN eradication to lead to a better prognosis in cancer treatment or an improvement in chemotherapy. In addition, no studies have linked good dental hygiene to CRC. FN is a type of bacteria that colonises the oral cavity, and therefore the relationship between FN amounts in the oral cavity and in the colon mucosa could be examined.

The main limitation of this systematic review was that it included studies published in MEDLINE, accessed via PubMed, and not in other databases or doctoral dissertations on the topic. Hence we assume that published information, however limited, might have been missed; on the other hand, such information could be presumed to be of little significance. Regarding the language limitation, only studies published in English or Spanish were included, although most of the journals indexed in MEDLINE were published in English, and only two studies were excluded for this reason. Even the association of higher rates of FN in CRC samples does not imply a causality that could point to a preventive strategy. It could stem from facilitation by tumour tissue of subsequent FN infection.

Conclusions

Based on the results of this systematic review and meta-analysis, we found that there is an association between the presence of FN and CRC. Lastly, to arrive at a definitive conclusion, further comparative studies must be conducted in sufficient numbers of patients using a combination of multiple microbiological techniques for individual subjects and samples, with simultaneous analysis of neoplastic tissue and healthy tissue by means of standardised techniques with suitable sensitivity.

Conflicts of interest

The authors declare that they have no conflicts of interest.

References
[1]
L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal.
Global cancer statistics, 2012.
CA Cancer J Clin, 65 (2015), pp. 87-108
[2]
D. Furman, J. Campisi, E. Verdin, P. Carrera-Bastos, S. Targ, C. Franceschi, et al.
Chronic inflammation in the etiology of disease across the life span.
Nat Med, 25 (2019), pp. 1822-1832
[3]
V.S. Benson, J. Patnick, A.K. Davies, M.R. Nadel, R.A. Smith, W.S. Atkin.
International Colorectal Cancer Screening Network. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries.
Int J Cancer, 122 (2008), pp. 1357-1367
[4]
A.D. Kostic, E. Chun, L. Robertson, J.N. Glickman, C.A. Gallini, M. Michaud, et al.
Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment.
Cell Host Microbe, 14 (2013), pp. 207-215
[5]
J. Yu, Q. Feng, S.H. Wong, D. Zhang, Q.Y. Liang, Y. Qin, L. Tang, et al.
Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer.
Gut, 66 (2017), pp. 70-78
[6]
L.A. Guevara Jr., A.C.F. Afable, P.J.O. Belza, K.J.S. Dy, S.J.Q. Lee, T.T. Sy-Ortin, et al.
Immunogenicity of a Fap2 peptide mimotope of Fusobacterium nucleatum and its potential use in the diagnosis of colorectal cancer.
Infect Agent Cancer, 13 (2018), pp. 11
[7]
Zerón, A. Gutiérrez de Velasco, D. Porras Lira.
Fusobacterium nucleatum ¿Un patógeno periodontal promotor de carcinogénesis colorrectal?.
Revista ADM, 73 (2016), pp. 280-285
[8]
J.P. Nougayrède, S. Homburg, F. Taieb, M. Boury, E. Brzuszkiewicz, G. Gottschalk, et al.
Escherichia coli induces DNA double-strand breaks in eukaryotic cells.
Science, 313 (2006), pp. 848-851
[9]
M. Xu, M. Yamada, M. Li, H. Liu, S.G. Chen, Y.W. Han.
FadA from Fusobacterium nucleatum utilizes both secreted and nonsecreted forms for functional oligomerization for attachment and invasion of host cells.
J Biol Chem, 282 (2007), pp. 25000-25009
[10]
Y.N. Yu, T.C. Yu, H.J. Zhao, T.T. Sun, H.M. Chen, H.Y. Chen, et al.
Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment.
Oncotarget, 6 (2015), pp. 32013-32026
[11]
A. Idrissi Janati, I. Karp, H. Sabri, E. Emami.
Is a Fusobacterium nucleatum infection in the colon a risk factor for colorectal cancer? A systematic review and meta-analysis protocol.
[12]
R. DerSimonian, N. Laird.
Meta-analysis in clinical trials.
Control Clin Trials, 7 (1986), pp. 177-188
[13]
C.B. Begg, M. Mazumdar.
Operating characteristics of a rank correlation test for publication bias.
Biometrics, 50 (1994), pp. 1088-1101
[14]
M. Egger, G. Davey Smith, M. Schneider, C. Minder.
Bias in meta-analysis detected by a simple, graphical test.
[15]
M. Castellarin, R.L. Warren, J.D. Freeman, L. Dreolini, M. Krzywinski, J. Strauss, et al.
Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma.
Genome Res, 22 (2012), pp. 299-306
[16]
M.R. Rubinstein, X. Wang, W. Liu, Y. Hao, G. Cai, Y.W. Han.
Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin.
Cell Host Microbe, 14 (2013), pp. 195-206
[17]
R.L. Warren, D.J. Freeman, S. Pleasance, P. Watson, R.A. Moore, K. Cochrane, et al.
Co-occurrence of anaerobic bacteria in colorectal carcinomas.
Microbiome, 1 (2013), pp. 16
[18]
L. Flanagan, J. Schmid, M. Ebert, P. Soucek, T. Kunicka, V. Liska, J. Bruha, et al.
Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome.
Eur J Clin Microbiol Infect Dis, 33 (2014), pp. 1381-1390
[19]
L. Mira-Pascual, R. Cabrera-Rubio, S. Ocon, P. Costales, A. Parra, A. Suarez, et al.
Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers.
J Gastroenterol, 50 (2015), pp. 167-179
[20]
T. Tahara, E. Yamamoto, H. Suzuki, R. Maruyama, W. Chung, J. Garriga, et al.
Fusobacterium in colonic flora and molecular features of colorectal carcinoma.
Cancer Res, 74 (2014), pp. 1311-1318
[21]
M. Ito, S. Kanno, K. Nosho, Y. Sukawa, K. Mitsuhashi, H. Kurihara, et al.
Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway.
Int J Cancer, 137 (2015), pp. 1258-1268
[22]
K. Mima, Y. Sukawa, R. Nishihara, Z.R. Qian, M. Yamauchi, K. Inamura, et al.
Fusobacterium nucleatum and T cells in colorectal carcinoma.
JAMA Oncol, 1 (2015), pp. 653-661
[23]
M.H. Fukugaiti, A. Ignacio, M.R. Fernandes, U. Ribeiro Júnior, V. Nakano, M.J. Avila-Campos.
High occurrence of Fusobacterium nucleatum and Clostridium difficile in the intestinal microbiota of colorectal carcinoma patients.
Braz J Microbiol, 46 (2015), pp. 1135-1140
[24]
K. Nosho, Y. Sukawa, Y. Adachi, M. Ito, K. Mitsuhashi, H. Kurihara, et al.
Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer.
World J Gastroenterol, 22 (2016), pp. 557-566
[25]
J. Repass, N. Maherali, K. Owen.
Reproducibility project: cancer biology; reproducibility project cancer biology. Registered report: Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma.
[26]
Y.Y. Li, Q.X. Ge, J. Cao, Y.J. Zhou, Y.L. Du, B. Shen, et al.
Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients.
World J Gastroenterol, 22 (2016), pp. 3227-3233
[27]
J. Yu, Y. Chen, X. Fu, X. Zhou, Y. Peng, L. Shi, et al.
Invasive Fusobacterium nucleatum may play a role in the carcinogenesis of proximal colon cancer through the serrated neoplasia pathway.
Int J Cancer, 139 (2016), pp. 1318-1326
[28]
K. Mima, R. Nishihara, Zr Qian, Y. Cao, Y. Sukawa, Ja Nowak, et al.
Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.
Gut, 65 (2016), pp. 1973-1980
[29]
Y. Suehiro, K. Sakai, M. Nishioka, S. Hashimoto, T. Takami, S. Higaki, et al.
Highly sensitive stool DNA testing of Fusobacterium nucleatum as a marker for detection of colorectal tumours in a Japanese population.
Ann Clin Biochem., 54 (2017), pp. 86-91
[30]
Q. Liang, J. Chiu, Y. Chen, Y. Huang, A. Higashimori, J. Fang, et al.
Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer.
Clin Cancer Res, 23 (2017), pp. 2061-2070
[31]
S.H. Wong, T.N.Y. Kwong, T.C. Chow, A.K.C. Luk, R.Z.W. Dai, G. Nakatsu, et al.
Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia.
[32]
R.S. Mehta, R. Nishihara, Y. Cao, M. Song, K. Mima, Z.R. Qian, et al.
Association of dietary patterns with risk of colorectal cancer subtypes classified by Fusobacterium nucleatum in tumor tissue.
JAMA Oncol, 3 (2017), pp. 921-927
[33]
Y. Chen, Y. Peng, J. Yu, T. Chen, Y. Wu, L. Shi, et al.
Invasive Fusobacterium nucleatum activates beta-catenin signaling in colorectal cancer via a TLR4/P-PAK1 cascade.
Oncotarget, 8 (2017), pp. 31802-31804
[34]
X. Ye, R. Wang, R. Bhattacharya, D.R. Boulbes, F. Fan, L. Xia, et al.
Fusobacterium nucleatum subspecies animalis influences proinflammatory cytokine expression and monocyte activation in human colorectal tumors.
Cancer Prev Res (Phila), 10 (2017), pp. 398-409
[35]
E.L. Amitay, S. Werner, M. Vital, D.H. Pieper, D. Höfler, I.J. Gierse, et al.
Fusobacterium and colorectal cancer: causal factor or passenger? Results from a large colorectal cancer screening study.
Carcinogenesis, 38 (2017), pp. 781-788
[36]
H.E. Park, J.H. Kim, N.Y. Cho, H.S. Lee, G.H. Kang.
Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma.
Virchows Arch, 471 (2017), pp. 329-336
[37]
V. Eklöf, A. Löfgren-Burström, C. Zingmark, S. Edin, P. Larsson, P. Karling, et al.
Cancer-associated fecal microbial markers in colorectal cancer detection.
Int J Cancer, 141 (2017), pp. 2528-2536
[38]
S. Bullman, C.S. Pedamallu, E. Sicinska, T.E. Clancy, X. Zhang, D. Cai, et al.
Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer.
Science, 358 (2017), pp. 1443-1448
[39]
J.L. Drewes, J.R. White, C.M. Dejea, P. Fathi, T. Iyadorai, J. Vadivelu, et al.
High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectal cancer consortia.
NPJ Biofilms Microbiomes, 3 (2017), pp. 34
[40]
Y. Yamaoka, Y. Suehiro, S. Hashimoto, T. Hoshida, M. Fujimoto, M. Watanabe, et al.
Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population.
J Gastroenterol, 53 (2018), pp. 517-524
[41]
Z. Dai, O.O. Coker, G. Nakatsu, W.K.K. Wu, L. Zhao, Z. Chen, et al.
Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers.
[42]
L. Liu, F.K. Tabung, X. Zhang, J.A. Nowak, Z.R. Qian, T. Hamada, et al.
Diets that promote colon inflammation associate with risk of colorectal carcinomas that contain Fusobacterium nucleatum.
Clin Gastroenterol Hepatol, 16 (2018), pp. 1622-1631
[43]
T. Chen, Q. Li, J. Wu, Y. Wu, W. Peng, H. Li, et al.
Fusobacterium nucleatum promotes M2 polarization of macrophages in the microenvironment of colorectal tumours via a TLR4-dependent mechanism.
Cancer Immunol Immunother, 67 (2018), pp. 1635-1646
[44]
S. Guo, L. Li, B. Xu, M. Li, Q. Zeng, H. Xiao, et al.
A simple and novel fecal biomarker for colorectal cancer: ratio of Fusobacterium nucleatum to probiotics populations, based on their antagonistic effect.
Clin Chem, 64 (2018), pp. 1327-1337
[45]
Y. Komiya, Y. Shimomura, T. Higurashi, Y. Sugi, J. Arimoto, S. Umezawa, et al.
Patients with colorectal cancer have identical strains of Fusobacterium nucleatum in their colorectal cancer and oral cavity.
[46]
D.W. Lee, S.W. Han, J.K. Kang, J.M. Bae, H.P. Kim, J.K. Won, et al.
Association between Fusobacterium nucleatum, pathway mutation, and patient prognosis in colorectal cancer.
Ann Surg Oncol, 25 (2018), pp. 3389-3395
[47]
S. Rezasoltani, H. Asadzadeh Aghdaei, H. Dabiri, A. Akhavan Sepahi, M.H. Modarressi, E. Nazemalhosseini Mojarad.
The association between fecal microbiota and different types of colorectal polyp as precursors of colorectal cancer.
Microb Pathog, 124 (2018), pp. 244-249
[48]
T. Hamada, X. Zhang, K. Mima, S. Bullman, Y. Sukawa, J.A. Nowak, et al.
Fusobacterium nucleatum in colorectal cancer relates to immune response differentially by tumor microsatellite instability status.
Cancer Immunol Res, 6 (2018), pp. 1327-1336
[49]
H.J. Oh, J.H. Kim, J.M. Bae, H.J. Kim, N.Y. Cho, G.H. Kang.
Prognostic impact of Fusobacterium nucleatum depends on combined tumor location and microsatellite instability status in stage II/III colorectal cancers treated with adjuvant chemotherapy.
J Pathol Transl Med, 53 (2019), pp. 40-49
[50]
M.A. Proença, J.M. Biselli, M. Succi, F.E. Severino, G.N. Berardinelli, A. Caetano, et al.
Relationship between Fusobacterium nucleatum, inflammatory mediators and microRNAs in colorectal carcinogenesis.
World J Gastroenterol, 24 (2018), pp. 5351-5365
[51]
S. Zhang, Y. Yang, W. Weng, B. Guo, G. Cai, Y. Ma, et al.
Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer.
J Exp Clin Cancer Res, 38 (2019), pp. 14
[52]
K. Saito, S. Koido, T. Odamaki, M. Kajihara, K. Kato, S. Horiuchi, et al.
Metagenomic analyses of the gut microbiota associated with colorectal adenoma.
PLoS One, 14 (2019), pp. e0212406
[53]
M. Guo, E. Xu, D. Ai.
Inferring bacterial infiltration in primary colorectal tumors from host whole genome sequencing data.
Front Genet, 10 (2019), pp. 213
[54]
Y.Y. Feng, D.Z. Zeng, Y.N. Tong, X.X. Lu, G.D. Dun, B. Tang, et al.
Alteration of microRNA-4474/4717 expression and CREB-binding protein in human colorectal cancer tissues infected with Fusobacterium nucleatum.
PLoS One, 14 (2019), pp. e0215088
[55]
H.S. Tunsjø, G. Gundersen, F. Rangnes, J.C. Noone, A. Endres, V. Bemanian.
Detection of Fusobacterium nucleatum in stool and colonic tissues from Norwegian colorectal cancer patients.
Eur J Clin Microbiol Infect Dis, 38 (2019), pp. 1367-1376
[56]
C. Bundgaard-Nielsen, U.T. Baandrup, L.P. Nielsen, S. Sørensen.
The presence of bacteria varies between colorectal adenocarcinomas, precursor lesions and non-malignant tissue.
BMC Cancer, 19 (2019), pp. 399
[57]
D.C. Guven, O. Dizdar, A. Alp, F.N. Akdoğan Kittana, D. Karakoc, E. Hamaloglu, et al.
Analysis of Fusobacterium nucleatum and Streptococcus gallolyticus in saliva of colorectal cancer patients.
Biomark Med, 13 (2019), pp. 725-735
[58]
S. Yachida, S. Mizutani, H. Shiroma, S. Shiba, T. Nakajima, T. Sakamoto, et al.
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer.
Nat Med, 25 (2019), pp. 968-976
[59]
P.H.M. Leung, R. Subramanya, Q. Mou, K.T. Lee, F. Islam, V. Gopalan, et al.
Characterization of mucosa-associated microbiota in matched cancer and non-neoplastic mucosa from patients with colorectal cancer.
Front Microbiol, 10 (2019), pp. 1317
[60]
A.T. Kunzmann, M.A. Proença, H.W. Jordao, K. Jiraskova, M. Schneiderova, M. Levy, et al.
Fusobacterium nucleatum tumor DNA levels are associated with survival in colorectal cancer patients.
Eur J Clin Microbiol Infect Dis, 38 (2019), pp. 1891-1899
[61]
J. Butt, M. Jenab, M. Pawlita, K. Overvad, A. Tjonneland, A. Olsen, et al.
Antibody responses to Fusobacterium nucleatum proteins in prediagnostic blood samples are not associated with risk of developing colorectal cancer.
Cancer Epidemiol Biomarkers Prev, 28 (2019), pp. 1552-1555
[62]
A.C. De Carvalho, L. de Mattos Pereira, J.G. Datorre, W. Dos Santos, G.N. Berardinelli, M.M. Matsushita, et al.
Microbiota profile and impact of Fusobacterium nucleatum in colorectal cancer patients of barretos cancer hospital.
Front Oncol, 9 (2019), pp. 813
[63]
Y. Chen, Y. Lu, Y. Ke, Y. Li.
Prognostic impact of the Fusobacterium nucleatum status in colorectal cancers.
Medicine (Baltimore), 98 (2019),
[64]
K. Mima, Y. Sakamoto, K. Kosumi, Y. Ogata, K. Miyake, Y. Hiyoshi, et al.
Mucosal cancer-associated microbes and anastomotic leakage after resection of colorectal carcinoma.
Surg Oncol, 32 (2020), pp. 63-68
[65]
J.Q. Liang, T. Li, G. Nakatsu, Y.X. Chen, T.O. Yau, E. Chu, et al.
A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer.
[66]
K. Haruki, K. Kosumi, T. Hamada, T.S. Twombly, J.P. Väyrynen, S.A. Kim, et al.
Association of autophagy status with amount of Fusobacterium nucleatum in colorectal cancer.
J Pathol, 250 (2020), pp. 397-408
[67]
S. Chen, T. Su, Y. Zhang, A. Lee, J. He, Q. Ge, et al.
Fusobacterium nucleatum promotes colorectal cancer metastasis by modulating KRT7-AS/KRT7.
Gut Microbes, 11 (2020), pp. 511-525
[68]
H. Hussan, S.K. Clinton, K. Roberts, M.T. Bailey.
Fusobacterium’s link to colorectal neoplasia sequenced: a systematic review and future insights.
World J Gastroenterol., 23 (2017), pp. 8626-8650
[69]
K. Yamamura, Y. Baba, K. Miyake, K. Nakamura, H. Shigaki, K. Mima, et al.
Fusobacterium nucleatum in gastroenterological cancer: evaluation of measurement methods using quantitative polymerase chain reaction and a literature review.
Oncol Lett, 14 (2017), pp. 6373-6378
[70]
T. Yu, F. Guo, Y. Yu, T. Sun, D. Ma, J. Han, et al.
Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy.
[71]
X. Yan, L. Liu, H. Li, H. Qin, Z. Sun.
Clinical significance of Fusobacterium nucleatum, epithelial-mesenchymal transition, and cancer stem cell markers in stage III/IV colorectal cancer patients.
Onco Targets Ther, 10 (2017), pp. 5031-5046
[72]
A. Ramos, M.T. Hemann.
Drugs, bugs, and cancer: Fusobacterium nucleatum pro-motes chemoresistance in colorectal cancer.
[73]
A. Bashir, A.Y. Miskeen, A. Bhat, K.M. Fazili, B.A. Ganai.
Fusobacterium nucleatum: an emerging bug in colorectal tumorigenesis.
Eur J Cancer Prev, 24 (2015), pp. 373-385
[74]
C.M. Dejea, E.C. Wick, E.M. Hechenbleikner, J.R. White, J.L. Mark Welch, B.J. Rossetti, et al.
Microbiota organization is a distinct feature of proximal colorectal cancers.
Proc Natl Acad Sci U S A, 111 (2014),
[75]
A. Bradford-Hill.
The environment and disease: association and cau sation.
Proc R Soc Med, 58 (1965), pp. 295-300
[76]
C. Mantilla, Suárez-Mellado, A. Duque-Jaramillo, M.C. Navas.
Mecanismos de señalización por β-catenina y su papel en la carcinogénesis.
CES Med, 29 (2015), pp. 109-128

Please cite this article as: Villar-Ortega P, Expósito-Ruiz M, Gutiérrez-Soto M, Ruiz-Cabello Jiménez M, Navarro-Marí JM, Gutiérrez-Fernández J. La asociación entre Fusobacterium nucleatum y el cáncer colorrectal: una revisión sistemática y metaanálisis. Enferm Infecc Microbiol Clin. 2022;40:224–234.

Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos